BRIEF—CMO among Nouscom appointments

Nouscom, a clinical stage immuno-oncology company developing off-the-shelf and personalized viral vectored immunotherapies, has announced the promotion of Sven Gogov to chief medical officer (CMO) and the appointment of Maria Arce-Tomas as vice president, head of regulatory affairs.

Dr Gogov succeeds Patricia Delaite, who is leaving the company. Prior to joining Nouscom in October 2021 to become vice president of clinical development, he was at Incyte (Nasdaq: INCY), where he served as executive director, global immuno-oncology, responsible for developing the clinical strategy and trial execution for several assets targeting the tumor microenvironment. He also had spells at Novartis (NOVN: VX), OSI Pharmaceuticals and AstraZeneca (LSE: AZN).

Dr Arce-Tomas joins Nouscom from Spain's PharmaMar (BME: PHM) where she was global head of regulatory affairs responsible for the entire product portfolio of the group. She also held senior corporate leadership positions at various pharma and biotech companies including Novo Nordisk (NOV: N), GE Healthcare (NYSE: GE), Takeda (TYO: 4502), Abbott (NYSE: ABT), Norgine and GSK (LSE: GSK).

Marina Udier, the Swiss firm's chief executive, said: "Sven joined Nouscom in October last year as part of our clinical development expansion and has been instrumental in leading the clinical development strategy for our viral vector immunotherapies. He is an outstanding clinical leader with deep expertise in targeted therapeutics and oncology research, garnered through his successful drug development career."

"I am also delighted to welcome Maria, [who] has extensive global regulatory affairs experience in the pharmaceutical industry and her and Sven’s expertise will be critical as we advance our clinical programs and initiate Phase II studies of NOUS-209."